



F A X C O V E R

Date: November 15, 2004 **Number of pages** (including cover): 118
To: Examiner Sheridan Swope, U.S. Patent and Trademark Office
Fax No.: (571) 273-0943
Serial No.: 09/802,285
Title: **HEPARINASE III AND USES THEREOF**
From: Janice A. Vatland, Ph.D.
Direct dial: 617.646.8261
Our File #: M0656.70063US00

CERTIFICATE OF FACSIMILE TRANSMISSION 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being transmitted via facsimile to the attention of Examiner Sheridan Swope, FAX number (571) 273-0943, at the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, in accordance with 37 C.F.R. §1.6(d), on November 15, 2004.


Nicole Millette Hawes

ORIGINAL DOCUMENTS WILL NOT BE MAILED.

Examiner Swope:

Attached are the references we discussed in our earlier telephone conversation. We have also included a new Form PTO-1449 for your review and initials.

Janice Vatland

This transmission contains confidential information intended for use only by the above-named recipient. Reading, discussing, distributing, or copying this message by anyone other than the named recipient, or his or her employees or agents, is strictly prohibited. If you have received this fax in error, please notify us immediately by telephone (collect), and return the original message to us at the address below via the U.S. Postal Service.

IF YOU DID NOT RECEIVE ALL OF THE PAGES OF THIS TRANSMISSION, OR IF ANY OF THE PAGES ARE ILLEGIBLE, PLEASE CALL 617.646.8000 IMMEDIATELY.

Wolf Greenfield Fax Number: 617.646.8646

Wolf, Greenfield & Sacks, P.C. | 600 Atlantic Avenue | Boston, Massachusetts 02210-2206
617.646.8000 | fax 617.646.8646 | www.wolfgreenfield.com

PATENTS TRADEMARKS COPYRIGHTS TECHNOLOGY TRANSFERS LITIGATION

842448_1.DOC

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 09/802,285		ATTY. DOCKET NO.: M0656/7063	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: March 8, 2001			
				APPLICANT: Liu et al.			
				GROUP ART UNIT: 1614		EXAMINER: Unassigned	
Sheet	1	of	1				

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B10	EP	0 244 236	A2	Novo Industri A/S	11/04/1987	
	B11	EP	0 394 971	A1	KabiVitrum AB	10/31/1990	
	B12	WO	92/01003	A1	Board of Regents Univ. of TX System	01/23/1992	
	B13	WO	93/05167	A1	Children's Medical Center Corp.	03/18/1993	
	B14	WO	94/12618	A1	Massachusetts Institute of Technology	06/09/1994	
	B15	WO	95/13830	A1	Massachusetts Institute of Technology	05/26/1995	
	B16	WO	96/01648	A1	Ibex Technologies R and D, Inc.	01/25/1996	
	B17	PCT	US01/07464		Invitation to Pay Additional Fees	03/08/2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C49	AMEER, G.A. et al., "A New Approach to Regional Heparinization: Design and Development of a Novel Immobilized Heparinase Device", <i>Blood Purification Meeting Info: Third International Conference on Continuous Renal Replacement Therapies, San Diego, CA, USA, March 5-7, 1998, Pages 107-108, Vol. 16, No. 2, Abstract</i>	
	C50	BERRY, D. et al., "Distinct heparan sulfate glycosaminoglycans are responsible for mediating fibroblast growth factor-2 biological activity through different fibroblast growth factor receptors", <i>The FASEB Journal Express Article 10.1096/j.00-0661/jc.</i> , Published online April 6, 2001, Pages 1-19	
	C51	ERNST, S. et al., "Enzymatic Degradation of Glycosaminoglycans", <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 1995, Pages 387-444, Vol. 30, No. 5, CRC Press, Inc.	
	C52	MURPHY, P.R. et al., "Basic fibroblast growth factor binding and processing by human glioma cells", <i>Molecular and Cellular Endocrinology</i> , 1995, Pages 193-203, Vol. 114, No. 1-2, Elsevier Science Ireland Ltd.	
	C53	NATKE, B. et al., "Heparinase treatment of bovine smooth muscle cells inhibits fibroblast growth factor-2 binding to fibroblast growth factor receptor but not FGF-2 mediated cellular proliferation", <i>Angiogenesis</i> , 1999, Pages 249-257, Vol. 3, No. 3, Kluwer Academic Publishers Netherlands	
	C54	PADERA, R. et al., "FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling", <i>The FASEB Journal</i> , October 1999, Pages 1677-1687, Vol. 13, No. 13	

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

579136.1